Abdullah M. Alsalal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdullah M. Alsalal has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Salem Alkanaimsh
Department of Chemical Engineering, College of Engineering and Petroleum, Kuwait University, P.O. Box 5969, Safat, Kuwait City 13060, Kuwait
3 shared publications Fares Almomani
1 shared publication- Hesham El-Touney
Department of Chemical Engineering, College of Engineering and Petroleum, Kuwait University, P.O. Box 5969, Safat, Kuwait City 13060, Kuwait
1 shared publication - Khaled Aleidan1 shared publication
Mohammad Abotalib
1 shared publication- Nourah Alnajdi1 shared publication
Latest Publications
- Open Access
- 10 October 2026
- Published by Elsevier in Journal of Engineering Research
Replacing oil-based mud with high-performance water-based mud in GCC reactive shale: Techno-economic, life-cycle, and risk evidence
- 10 October 2026
- Published by Elsevier in Journal of Engineering Research
Open AccessReplacing oil-based mud with high-performance water-based mud in GCC reactive shale: Techno-economic, life-cycle, and risk evidence
- Open Access
- 13 July 2026
- Published by Elsevier in Biomass and Bioenergy
- Vol. 217
From wastewater to value: Techno-Economic and life-cycle assessment of a continuous microalgae biorefinery for high-value metabolites and bioenergy
- 13 July 2026
- Published by Elsevier in Biomass and Bioenergy
- Vol. 217
Open AccessFrom wastewater to value: Techno-Economic and life-cycle assessment of a continuous microalgae biorefinery for high-value metabolites and bioenergy
- Open Access
- 20 November 2025
- Published by Elsevier in Chemical Engineering Journal Advances
- Vol. 25
Improving sensitive-reactant efficiency in site-specific PEGylation via semi-batch processing: simulation-based evaluation under throughput constraints
- 20 November 2025
- Published by Elsevier in Chemical Engineering Journal Advances
- Vol. 25
Open AccessImproving sensitive-reactant efficiency in site-specific PEGylation via semi-batch processing: simulation-based evaluation under throughput constraints
- Open Access
Technoeconomic Analysis of Intensified PEGylated Biopharmaceutical Recombinant Protein Production: Alpha Antitrypsin as a Model Case
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the insufficient production of the AAT protein. Due to availability limitations, not all AATD patients receive protein therapy treatment. In this study, the technoeconomic analysis of different processes (conventional and intensified) producing 200 kg/year of PEGylated recombinant AAT (PEG-AAT) using a Chinese hamster ovary cell line was investigated. All bioprocesses consist of upstream, downstream, and PEGylation sections. A base-case model (process A) of the conventional fed-batch production bioreactor was developed using SuperPro Designer software (Version 13) to evaluate the economic feasibility of the process. The cost of goods (COG) was estimated to be approximately USD 387.6/g. Furthermore, an intensified process (B) was modeled and evaluated to reduce the COG. Process intensification was implemented in the process (N-1 perfusion bioreactor). The specific operating COG for process B was found to be 10% less than that of process A. Scenario analysis was performed to assess the impact of process capacity (100–1000 kg/year) and cell-specific productivity (30–90 pg/cell/day). With an increase in process capacity, the specific operating COG was reduced for all processes. Increasing cell-specific productivity decreases the specific operating COG at different rates for each process, depending on the titer level. Future investigations into the PEGylation section are required since it has the highest COG of all the sections.
Open AccessTechnoeconomic Analysis of Intensified PEGylated Biopharmaceutical Recombinant Protein Production: Alpha Antitrypsin as a Model Case
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the insufficient production of the AAT protein. Due to availability limitations, not all AATD patients receive protein therapy treatment. In this study, the technoeconomic analysis of different processes (conventional and intensified) producing 200 kg/year of PEGylated recombinant AAT (PEG-AAT) using a Chinese hamster ovary cell line was investigated. All bioprocesses consist of upstream, downstream, and PEGylation sections. A base-case model (process A) of the conventional fed-batch production bioreactor was developed using SuperPro Designer software (Version 13) to evaluate the economic feasibility of the process. The cost of goods (COG) was estimated to be approximately USD 387.6/g. Furthermore, an intensified process (B) was modeled and evaluated to reduce the COG. Process intensification was implemented in the process (N-1 perfusion bioreactor). The specific operating COG for process B was found to be 10% less than that of process A. Scenario analysis was performed to assess the impact of process capacity (100–1000 kg/year) and cell-specific productivity (30–90 pg/cell/day). With an increase in process capacity, the specific operating COG was reduced for all processes. Increasing cell-specific productivity decreases the specific operating COG at different rates for each process, depending on the titer level. Future investigations into the PEGylation section are required since it has the highest COG of all the sections.